Literature DB >> 32179909

Recurrent IDH mutations in high-grade meningioma.

Corey M Gill1, Joshua Loewenstern1, John W Rutland1, Hanane Arib2, Nancy Francoeur2, Ying-Chih Wang2, Nataly Fishman2, Margaret Pain1, Melissa Umphlett3, Yayoi Kinoshita3, Russell B McBride3,4, Joshua Bederson1, Michael Donovan3, Melissa Smith2, Robert Sebra5, Raj K Shrivastava1, Mary Fowkes3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32179909      PMCID： PMC7339895          DOI： 10.1093/neuonc/noaa065

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  4 in total

Review 1.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 3.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

4.  Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Authors:  Margaret Pain; Huaien Wang; Eunjee Lee; Maya Strahl; Wissam Hamou; Robert Sebra; Jun Zhu; Raymund L Yong
Journal:  Oncotarget       Date:  2017-12-20
  4 in total
  4 in total

1.  NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.

Authors:  John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

2.  SWI/SNF chromatin remodeling complex alterations in meningioma.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-14       Impact factor: 4.553

3.  Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.

Authors:  Antoine Devalckeneer; Rabih Aboukais; Maxime Faisant; Philippe Bourgeois; Vannod-Michel Quentin; Claude-Alain Maurage; Fabienne Escande; Jean-Paul Lejeune
Journal:  Neurosurg Rev       Date:  2021-11-30       Impact factor: 3.042

4.  Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.

Authors:  Erik A Williams; Sandro Santagata; Hiroaki Wakimoto; Ganesh M Shankar; Fred G Barker; Radwa Sharaf; Abhinav Reddy; Phoebe Spear; Brian M Alexander; Jeffrey S Ross; Priscilla K Brastianos; Daniel P Cahill; Shakti H Ramkissoon; Tareq A Juratli
Journal:  Acta Neuropathol Commun       Date:  2020-10-21       Impact factor: 7.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.